Reven initiated a stability study for its vascular drug, RJX.

Reven, in conjunction with its research partner, validated an analytical assay for its vascular drug, RJX.

USPTO grants Reven two more patent.

Shareholder Spring Update posted to the Investor Portal.

Year End Shareholder Update Posted in Investor Portal

Reven receives first patent number from the US Patent and Trademark office.

Reven announces US clinical development plans for RJX.

Reven completes fitup in new office space and signs long term lease.